Health Care·Pharmaceuticals·$789.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.33 | N/A | -2.12% |
management commentary, guidance changes, and full analysis available with Pro.
| -2.12% |
Tone: Cautiously Optimistic
Management expressed confidence in their pipeline and future growth. However, they acknowledged the challenges faced in the current quarter.
We are focused on delivering innovative solutions for patients.
Our pipeline remains strong, and we are committed to our long-term goals.
Eli Lilly's earnings report indicates a slight miss on EPS expectations, which may raise concerns among investors. The lack of revenue data and guidance could lead to uncertainty in the stock's performance. Management's focus on innovation and a strong pipeline suggests a long-term positive outlook, but immediate reactions may be muted due to the EPS miss.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SOUTHERN COPPER CORP
Apr 29, 2019